Durvalumab (DUR) effectiveness in advanced biliary tract cancer (aBTC) patients based on real-world data evidence.

Authors: Jesus Rodriguez-Pascual, Gema Hernández, Lisardo Ugidos, Alejandro Parralejo, Juan Diego Rodriguez-Castaño, Juan Jose Serrano, Angel Ayuso

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.598

Source: Full article

---

Abstract

598